Track market-moving stories before they get noisy

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of Duolingo, Inc. (NASDAQ: DUOL) between May 2, 2025 to February 26, 2026, inclusive (the "Class Period"), of the important December 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Duolingo Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Duolingo class action, go to https://rosenlegal.com/cases/duolingo-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Daily Active User ("DAU") growth rates were being leveraged against deliberately added user friction in the form of significant increases in ad volume, subscription tier upsells, and worsened product quality, and defendants understood that any amount of user friction would cause users to leave the app and, ultimately, negatively impact DAU growth rates; (2) Duolingo's rigorous A/B testing demonstrated to defendants that increased friction in the free user experience was having negative impacts on DAU growth rates; (3) Duolingo's quickly generated AI content was worsening the quality of Duolingo's product offerings, negatively impacting the user experience and user trends, and threatening the sustainability of Duolingo's financial performance; and (4) far from driving sustained growth and strong user momentum through content and "product improvements" that "get improved retention," Duolingo's constant A/B testing informed Duolingo that its monetization push and lower-quality, rapidly generated AI content were degrading the Duolingo product experience and the value proposition of its subscription tiers. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Duolingo class action, go to https://rosenlegal.com/cases/duolingo-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320797

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

TORONTO--(BUSINESS WIRE)--Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), an owner and operator of U.S. grocery-anchored real estate, announced today that it has obtained an interim order (the “Interim Order”) of the Ontario Superior Court of Justice (Commercial List) (the “Court”) in connection with the proposed acquisition by EP/BRX Holdings LLC (the “Purchaser”), a joint venture between an affiliate of Brixmor Property Group Inc. and affiliates of Everview Partners, L.P., of all.

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AST SpaceMobile, Inc. (NASDAQ: ASTS) between March 4, 2025 and July 15, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased AST SpaceMobile securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AST SpaceMobile class action, go to https://rosenlegal.com/cases/ast-spacemobile-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) AST SpaceMobile’s increasing capital requirements were likely to increase AST SpaceMobile’s debt load and share dilution with greater frequency and at greater scale than defendants had signaled to investors; (2) accordingly, defendants had overstated the sufficiency of AST SpaceMobile’s capital and liquidity position to achieve AST SpaceMobile’s strategic and business goals; (3) defendants likewise overstated the durability of AST SpaceMobile’s competitive position in the satellite D2C market; (4) even following the EchoStar Transaction, defendants continued overstating AST SpaceMobile’s competitive position in the satellite D2C market; (5) AST SpaceMobile was experiencing slow user adoption in the U.S. and Japan; (6) the foregoing was likely to have a significant negative impact on AST SpaceMobile’s business and financial prospects; and (7) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the AST SpaceMobile class action, go to https://rosenlegal.com/cases/ast-spacemobile-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased or otherwise acquired the Company's securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period").  This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of Hims as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-hims/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 2, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Hims & Hers Health and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On July 29, 2026, during market hours, the Federal Trade Commission ("FTC") announced that it had filed a lawsuit against the Company "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." The FTC further alleged that the Company fails to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'"

On this news, the price of Hims & Hers Health shares fell $4.32, or 14.73%, to close at $25.00 on July 29, 2026, on unusually heavy trading volume.

The case is Velanki v. Hims & Hers Health, Inc. et al., 26-cv-09313.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

SOURCE Kahn Swick & Foti, LLC

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology

, /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab.

Lunit and Summit Therapeutics The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.

Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumor microenvironment features without requiring additional stains or assays.

"Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations," said Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit. "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab."

"Summit is at the forefront of next-generation immuno-oncology development, and we are excited to support its efforts with Lunit SCOPE IO," said Brandon Suh, Lunit CEO. "By extracting quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, we believe SCOPE IO can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why."

This agreement reflects the growing importance of computational pathology in oncology drug development. Routine H&E slides contain rich information about tumor architecture, immune infiltration, stromal organization, and spatial interactions within the tumor microenvironment. However, traditional manual assessment can be difficult to scale and may not fully capture the quantitative and spatial complexity of the tumor-immune interface. AI-powered analysis offers the potential to convert these routinely generated pathology images into reproducible, high-dimensional biomarker data.

The companies expect the work to generate tumor microenvironment insights that may inform future translational research, exploratory biomarker strategies, and clinical development planning. No clinical outcome data are being announced as part of this release.

 *Lunit SCOPE products are for research use only. Not for use in diagnostic procedures or decisions.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit's license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit's license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab's specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab's design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 17 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251).

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit's positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China.

Akeso is actively conducting additional Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company's shares are listed on the Nasdaq Global Market (symbol "SMMT"). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Lunit Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected benefits of the collaboration, the potential use of AI-powered pathology in immuno-oncology development, and the potential application of tumor microenvironment analysis in biomarker research and clinical development. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Neither company undertakes any obligation to update these forward-looking statements, except as required by law.

Summit Forward-Looking Statements

Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about dilution to existing stockholders and potential adverse effects on the market price of the Company's common stock, including from future sales by AstraZeneca, the Company's broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca's ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company's reliance on AstraZeneca for the supply of AstraZeneca's products and other contributions to the clinical trials, the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program ("ATM Program"), the expected proceeds and uses thereof, the Company's estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a "positive study" as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

SOURCE Lunit Inc.

Well before the throttling this month of Ukraine's military access to Elon Musk's satellite communications system, the Biden and Trump administrations had several times asked SpaceX to turn its Starlink service on or off in various countries, according ​to six former senior US officials familiar with the matter.

During the presidency of Joe Biden, the requests included switching off the service to prevent Iranian proxy militias in Yemen and Lebanon from using Starlink to communicate, and activating the service to provide ‌internet access inside Iran and in Ukraine to support its military, said four of the former officials.

Similarly, President Donald Trump's administration asked Musk, who is CEO of SpaceX, to make the service available in Iran following US-Israeli strikes in 2025 and 2026, in hopes it would bolster internet access and communications for anti-government protesters, a former senior Trump official and a person familiar with the matter told Reuters.

All of the people spoke on condition of anonymity. The previous US requests about Starlink access are being reported here for the first time.

The recent blowup over restrictions to Ukraine's use of SpaceX satellite services has raised questions about the ties between the US government and Musk, whose company owns systems vital to the ​US military and to US allies.

The Biden-era and Trump requests to Musk show a close relationship in which US administrations rely to an unprecedented degree on a private-sector company to help implement foreign policy.

The recent limits on Ukraine, despite being a US ally, have also rattled ​officials in Europe, some of whom argue that Europe must develop its own military satellite communications capabilities because no viable short-term alternative currently exists.

STARSHIELD RESTRICTIONS HOBBLE UKRAINE MILITARY
Ukrainian President Volodymyr Zelenskiy said last week that his country's access ⁠to Starshield, the military version of the Starlink system, had been intentionally limited, interfering with the performance of the country’s military drones. He also said the speeds were reduced for Starlink, which Ukraine uses for some military activities including defense against Russian missile attacks.

Reuters has reported that the order to throttle Starshield ​came from inside the White House. The Trump administration has acknowledged the slowdown but has not said whether it gave the order.

The White House, contacted for comment, referred Reuters to Trump's remarks on Friday, when he said he had not spoken with Musk about Starlink access issues for Ukraine and that "if there ​is a problem, I'll get it straightened out."

Halyna Yusypiuk, a spokesperson for the Ukrainian embassy in Washington, said Ukraine's priority is "to have the service restored to normal speed as soon as possible, as the lives of our people depend on it."

SpaceX did not respond to requests for comment, although Musk said in a social media post earlier this week: “Starshield systems are owned and controlled by the US government. Any limits on speed or usage are decided by the US military and ultimately (by the president of the United States).”

Democratic US Representative Jason Crow called on Friday for clarity about the recent changes to Ukraine's satellite service, saying there are risks to the US dependence on SpaceX.

"Unelected billionaires and private ​corporations should not decide what is in the best interest of America's national security," Crow said.

For Ukraine, the Starlink internet service has become the lifeblood of frontline communication between units, who say there is currently no rival to the capabilities of SpaceX's products.

Starshield receivers, largely impervious to radio jamming, are used ​as onboard guidance systems and to provide links to a remote pilot for Ukrainian drones, including deep behind Russian lines inside Ukraine.

MUSK'S INFLUENCE RAISES UNCERTAINTY
Musk's role as the strong-willed CEO of a company with outsized influence over US national security has at times raised questions over who is making decisions about SpaceX's satellite services.

The SpaceX CEO ‌is "supposed to be a ⁠business executive, with government contracts, and he's essentially making huge foreign policy decisions," said Armand Musey, president of Summit Ridge Group, a satellite industry consultancy.

"He's sufficiently ambiguous of a person that you don't know if his decisions are sort of his personal quirks, or it's because there's an influence elsewhere that's impacting him," Musey said.

In previous years, Musk has moved to limit Ukraine’s access to Starlink. In 2022, according to Reuters reporting, Musk ordered SpaceX personnel to cut Starlink coverage in areas Ukraine was trying to retake, a move that surprised White House officials.

Musk has said publicly that he refused a 2022 Ukrainian request to activate his satellite network in Crimea's port city of Sevastopol to aid an attack on Russia's fleet there, saying he feared complicity in a major act of war.

The Biden administration at times relied on Musk to help implement policy, five of the former officials said.

Biden officials coordinated with SpaceX to thwart US adversaries by ​cutting the service, and to help allies by expanding Starlink’s availability, they said.

They ​added that discussions between the government and SpaceX, which usually included ⁠Pentagon and White House officials, often focused on preventing groups such as the Iranian-linked Houthis in Yemen and Hezbollah in Lebanon from using Starlink terminals.

Biden officials several times shared intelligence with SpaceX that indicated that the Houthis and Hezbollah were using diverted Starlink terminals — hardware that made its way to the militants through intermediaries.

In October 2023, during fighting between Israel and Hezbollah militants in southern Lebanon, intelligence officials told the White House that individuals linked to Hezbollah could ​have gained access to Starlink terminals. Officials had similar concerns about the Houthis in Yemen in 2024 during a US air campaign against the Iran-linked group, five of the officials said.

In both cases, the administration contacted ​SpaceX and asked it to identify the ⁠terminals and shut them off. At least some of the terminals were deactivated, said two of the officials.

In a 2024 submission to the US Commerce Department's Bureau of Industry and Security, SpaceX said it works closely with US government agencies to secure export authorizations where required and to safeguard technology in support of US national security objectives and foreign policy goals.

Soon after Russia's full-scale invasion of Ukraine in 2022, Biden officials pushed SpaceX to expand Starlink use for the Ukrainian military, said two of the former officials.

In a separate instance, the Biden administration asked SpaceX to turn on Starlink in Iran during a protest movement launched in September 2022 after the ⁠death of Mahsa Amini, ​an Iranian arrested for not wearing her hijab properly, according to one of the former officials.

Starlink terminals were moved into the country with the help of the administration, said the ​official, who declined to say how many were transferred.

The Trump administration took a similar step earlier this year and discussed with Musk and SpaceX getting Starlink terminals into Iran and activated following US-Israeli strikes in the country in June 2025 and again in February 2026, a former senior Trump official and a person familiar with the matter told Reuters.

Neither the Trump administration nor SpaceX ​has publicly confirmed that those terminals were turned on. The Wall Street Journal reported in February that the US government had sent thousands of Starlink terminals into Iran.

Iran's delegation to the UN did not respond to a request for comment.

Boeing's (BA.N) dispute with a small Florida-based supplier has halted production of its 777 freighter ‌for nearly two months and disrupted output of the 767, including freighters and KC-46 aerial refueling tankers, according to Boeing workers and court filings.

Boeing filed a complaint in August alleging supplier Vaero had stopped delivering a critical wing component ​known as the trailing-edge rib kit, stalling work at the Everett, Washington, wing-production facility that supports ​the 777 freighter and 767 programs, according to a copy of the complaint ⁠reviewed by Reuters. The disruption was costing Boeing as much as $6.5 million a day, the complaint said.

Boeing ​said in the complaint that the trailing-edge rib kit was an "indispensable" part and Vaero was the sole supplier.

Although ​the companies reached a settlement in late September, production of the 777 freighter has yet to resume, according to three Boeing workers familiar with the matter. They declined to be named because they were not authorized to speak publicly.

The dispute ​also disrupted production of the 767, a widebody cargo and military aircraft, the people said. Since the ​settlement, Boeing has received some parts for the 767 line, according to one of the workers.

The prolonged disruption highlights ‌the fragility ⁠of aerospace supply chains, showing how a dispute involving a single supplier can halt production of aircraft that remain in strong demand.

The lawsuit was first reported by Law.com in August, but the nearly two-month production disruption has not previously been reported.

Boeing declined to comment. Vaero did not respond to requests for comment.

BRINGING ​PRODUCTION IN-HOUSE
Boeing is trying to ​bring production of the ⁠trailing-edge rib kit in-house, according to two of the people. The component is used in wing assembly for the 767 and current-generation 777 freighter. Boeing's 777X, ​which uses composite wings, has not been affected.

Without the Vaero parts, Boeing ​removed two partially ⁠assembled 777 freighters from its final assembly line, according to one Boeing worker.

Using data from aviation consultancy IBA, Reuters identified one of the aircraft as destined for FedEx (FDX.N).

FedEx did not respond to a request for comment.

Boeing ⁠has delivered ​21 777 freighters so far this year, company data show. ​It also has a handful of freighters whose wings were assembled before the dispute and could still be delivered before year-end, according ​to two of the Boeing workers.

Procter & Gamble (PG -2.12%) just had its best day in more than six years, with the stock jumping 5.6% on Thursday after the company delivered a surprisingly strong fiscal first quarter in a challenging environment.

During a time when many of its customers are struggling with inflation and a high cost of living, the household products giant reported 4% organic sales growth. That performance also represents a significant bounce from flat organic sales growth in the previous quarter, which helps explain why the stock had its best day since the market started soaring in the recovery from the pandemic crash in March 2020.

Organic volume was up 2.4%, and the company delivered strong results in beauty, fabric, and home care. Overall revenue rose 4% to $23.3 billion, which topped estimates at $22.8 billion.

Despite strong organic sales growth, core gross margin fell by 150 basis points, primarily due to higher commodity costs, reflecting higher oil prices than a year ago. Nonetheless, its productivity savings program helped improve selling, general, and administrative margins, and operating margin fell 70 basis points to 25.5%.

On the bottom line, the company reported core earnings per share of $2.00, up from $1.99 in the quarter a year ago, and ahead of the consensus at $1.89.

Image source: Getty Images.

Why the stock soared on the news P&G maintained its full-year core EPS guidance of $6.89-$7.11, and the company expects headwinds from higher commodity costs and oil prices to increase over the rest of the year.

Nonetheless, the company seemed to reverse earlier concerns about slumping growth, doing so at a time when many consumer brands are struggling. Four percent organic growth is outstanding for any mature consumer staples business, and that's the figure investors should focus on.

The news also came on a day when tech stocks plunged, and the sell-off may have beckoned more investors to rotate into P&G, which is seen as one of the most rock-solid, defensive stocks on the market.

$161.02-$3.48 (-2.12%)

NYSE · As of 4:00 PM ET 10/23/26

Is P&G a buy? The parent of Tide, Crest, and Pampers is a Dividend King, having increased its dividend for 70 years in a row. It now offers a dividend yield of 2.6%.

Still, P&G stock has been mostly flat over the last five years, and its commentary about increasing headwinds shows that investors should temper their expectations for the rest of the year.

For an investor looking for defensive, dividend-paying stocks or a safe place to ride out the volatility in the AI sector, P&G is a good choice. However, in the current environment, the upside potential for the stock seems moderate at best. There's a reason the stock's 6% gain yesterday was its best rally in several years.

Blink Charging (BLNK - Free Report) ended the recent trading session at $0.38, demonstrating a -3.44% change from the preceding day's closing price. This change lagged the S&P 500's 0.52% loss on the day. Meanwhile, the Dow lost 1.24%, and the Nasdaq, a tech-heavy index, lost 0.21%.

Coming into today, shares of the company had lost 29.25% in the past month. In that same time, the Computer and Technology sector lost 7.7%, while the S&P 500 lost 1.21%.

Investors will be eagerly watching for the performance of Blink Charging in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.04, marking a 60% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $20.92 million, indicating a 22.62% decline compared to the corresponding quarter of the prior year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.17 per share and revenue of $85.4 million, indicating changes of +73.02% and -17.48%, respectively, compared to the previous year.

Investors should also note any recent changes to analyst estimates for Blink Charging. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Blink Charging is currently sporting a Zacks Rank of #3 (Hold).

The Electronics - Miscellaneous Services industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 104, putting it in the top 43% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

In the latest close session, Zoetis (ZTS - Free Report) was down 1.18% at $81.03. The stock trailed the S&P 500, which registered a daily loss of 0.52%. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.

Shares of the animal health company have appreciated by 16.69% over the course of the past month, outperforming the Medical sector's gain of 3.23%, and the S&P 500's loss of 1.21%.

The investment community will be closely monitoring the performance of Zoetis in its forthcoming earnings report. The company is scheduled to release its earnings on November 5, 2026. The company's upcoming EPS is projected at $1.51, signifying a 11.18% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.3 billion, indicating a 4.11% decrease compared to the same quarter of the previous year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $6.14 per share and revenue of $9.24 billion, which would represent changes of -4.21% and -2.39%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. Zoetis is holding a Zacks Rank of #4 (Sell) right now.

Digging into valuation, Zoetis currently has a Forward P/E ratio of 13.35. This indicates a discount in contrast to its industry's Forward P/E of 16.81.

It is also worth noting that ZTS currently has a PEG ratio of 1.21. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Drugs industry had an average PEG ratio of 1.9.

The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow ZTS in the coming trading sessions, be sure to utilize Zacks.com.

CME futures launched, ETF filings hit the SEC, and two rival payment coins are pulling in opposite directions heading into year-end. One of them just made a 46% move in a single week, and the other can barely attract a…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Bitcoin Cash (CRYPTO:BCH) and Litecoin (CRYPTO:LTC) were created to offer cheaper, faster transactions than Bitcoin (CRYPTO:BTC). Both coins have attracted new Wall Street interest this fall of 2026: CME Group (NASDAQ:CME | CME Price Prediction) launched Bitcoin Cash futures, while Grayscale filed to convert its Bitcoin Cash and Litecoin trusts into ETFs. So, in the Bitcoin Cash vs. Litecoin battle, which coin has more potential to rise before December 31?

Bitcoin Cash is trading around $284, up 3.7% in the past 24 hours and 3.2% over the week. This rebound comes after a rough month for BCH, which saw prices swing between a high of $349 on September 24 and a low of $256 on October 15.

In contrast, Litecoin is trading near $58, down 1.2% in the past day and 2.8% over the week. It peaked at $80 on September 24 before slipping to about $57 by October 18.

Bitcoin Cash Has Further to Recover Than Litecoin

Market value, or market cap, is calculated by multiplying a coin’s price by the number of coins in circulation. Bitcoin Cash has a market cap of about $5.7 billion and trades 92.5% below its all-time high of $3,786. Litecoin, by comparison, has a market cap of about $4.5 billion and trades 85.9% below its peak of $410.

Both of these all-time highs may seem distant for the rest of 2026. This year, BCH has dropped 52.5% from $599 on December 31, 2025, while LTC has fallen about 24%. By comparison, Bitcoin has decreased only 7.2%, even as October has brought some weakness to the crypto market.

The volatility of BCH has been notable this year. It soared to $687 in mid-January but crashed to $180 by late June. Since July 25, however, BCH has risen by 31.2%, outperforming LTC’s 26.0% and Bitcoin’s 26.3%.

A reasonable 2026 goal for each coin is a return to its late-September highs. For BCH, that means reaching $366, which is about 28.8% above its current price. For LTC, that would mean returning to $80, a jump of about 38.7%.

CME Futures Boosted Bitcoin Cash, Yet Initial Trade Impact Was Minimal

Futures contracts let large funds trade BCH prices without holding the coin. CME announced these contracts on September 22, and by October 20, FalconX and GSR had executed the first block trade.

Initially, BCH surged after the announcement. In the week ending September 27, prices climbed from $250 to $366, marking a 46.5% range on the highest weekly volume seen since November 2025.

However, the coin moved little after the first trade, closing at $283 on October 20 and $275 on October 22—a 3.0% drop. Moreover, futures can also encourage traders to take short positions, which profit when prices decline.

Bitcoin Cash Is Still Waiting for an ETF Approval, While Litecoin’s ETF Has Gone Quiet

Grayscale submitted an updated registration with the SEC on September 11 to convert its Bitcoin Cash Trust into a spot ETF on NYSE Arca. A spot ETF would hold BCH directly, creating new demand whenever shares are purchased. The trust trades over the counter under the ticker BCHG, but the filing does not specify an approval timeline.

If approved, this could be BCH’s first U.S. spot ETF—a major potential boost for the coin.

Litecoin already has a spot ETF, the Canary Litecoin ETF (NASDAQ:LTCC), which trades in the U.S. Grayscale also filed in September to convert its Litecoin Trust to an ETF. However, demand for LTCC has been weak. LTCC saw no net flows on October 21, marking its second consecutive flat session.

LTC’s spike in September was short-lived; after reaching $80 on September 24 amid thin trading, it quickly fell back. Litecoin’s next halving, which will reduce the supply of new coins, is expected to occur in mid-2027, after the 2026 window closes.

Bitcoin Cash vs Litecoin: Which Has More Upside in 2026?
In summary, Bitcoin Cash appears to have more room to grow in 2026, especially if the SEC approves Grayscale’s BCHG conversion before December 31. BCH has experienced a deeper price drop, its September jump showed that news can move it fast, and its ETF is still a potential catalyst. Meanwhile, Litecoin’s ETF has traded with little enthusiasm, suggesting LTC may follow Bitcoin until its halving in 2027.

For BCH, important price points to watch include holding above $256 and breaking through $349 and $366. If the SEC remains quiet, a weekly close below $256 could push BCH back down to the $200 to $208 range.

Meanwhile, for LTC, breaking above $80 is crucial, while a drop below $57 could pull it down to around $54. Without a decisive SEC decision and a closing price above $366 for BCH, Litecoin’s smaller price decline may make it the more stable option.

Want Up To $3,000 In Stock? SoFi Is Giving New Active Invest Users Complimentary StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion; open a new Active Invest account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock.

From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.

Contact [email protected] for any questions or corrections.

In the latest trading session, Crocs (CROX - Free Report) closed at $119.26, marking a -1.43% move from the previous day. This change lagged the S&P 500's 0.52% loss on the day. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.

The stock of footwear company has fallen by 1.98% in the past month, lagging the Consumer Discretionary sector's gain of 4.8% and the S&P 500's loss of 1.21%.

The investment community will be paying close attention to the earnings performance of Crocs in its upcoming release. The company is slated to reveal its earnings on October 29, 2026. In that report, analysts expect Crocs to post earnings of $3.31 per share. This would mark year-over-year growth of 13.36%. Alongside, our most recent consensus estimate is anticipating revenue of $1 billion, indicating a 0.87% upward movement from the same quarter last year.

CROX's full-year Zacks Consensus Estimates are calling for earnings of $13.97 per share and revenue of $4.11 billion. These results would represent year-over-year changes of +11.67% and +1.68%, respectively.

Investors should also take note of any recent adjustments to analyst estimates for Crocs. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.14% higher. Currently, Crocs is carrying a Zacks Rank of #2 (Buy).

Valuation is also important, so investors should note that Crocs has a Forward P/E ratio of 8.66 right now. Its industry sports an average Forward P/E of 16.76, so one might conclude that Crocs is trading at a discount comparatively.

It is also worth noting that CROX currently has a PEG ratio of 1.01. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. CROX's industry had an average PEG ratio of 1.94 as of yesterday's close.

The Textile - Apparel industry is part of the Consumer Discretionary sector. This industry, currently bearing a Zacks Industry Rank of 184, finds itself in the bottom 26% echelons of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DICK'S Sporting Goods, Inc. (NYSE: DKS) between September 8, 2025 and August 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline.

SO WHAT: If you purchased DICK'S Sporting Goods common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DICK'S Sporting Goods class action, go to https://rosenlegal.com/cases/dicks-sporting-goods/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 3, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Dick's cleanup efforts concerning Foot Locker's inventory were not complete, and, in fact, Foot Locker remained saddled with unproductive and stagnant legacy footwear; (2) Foot Locker heavily relied on legacy footwear products that were particularly vulnerable to intensifying promotional pressures across the athletic footwear industry; (3) in turn, Dick's was significantly exposed to an industry-wide environment of excess inventory and resulting promotional activity; (4) accordingly, Dick's was unable to achieve the sales growth, margins, and profits it touted to investors; and (5) as a result of the above, defendants' positive statements about Dick's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DICK'S Sporting Goods class action, go to https://rosenlegal.com/cases/dicks-sporting-goods/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320630

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Gentex lowered its 2026 revenue guidance to approximately $2.65 billion, down from a prior range of $2.65 billion to $2.75 billion. Shareholders holding losses may have rights worth reviewing now.

, /PRNewswire/ -- The high end of Gentex Corporation's (NASDAQ: GNTX) 2026 revenue outlook dropped to its previous floor alongside third-quarter results on October 23, 2026, and GNTX shares fell to open at just $20.21, an overnight decline of more than 7%. If you bought Gentex stock and are now looking at a loss, you have rights as a shareholder. Investors who lost money on GNTX are encouraged to find out what rights they have as Gentex shareholders . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (212) 363-7500.

Before the third-quarter report, Gentex guided for 2026 revenue of $2.65 billion to $2.75 billion. The updated guidance is approximately $2.65 billion. That figure is the low end of the prior range and $50 million below its $2.70 billion midpoint. Third-quarter sales came in at $647.7 million, down from $655.2 million a year earlier. The Company's gross margin outlook decline as well, from a 35% midpoint to about 34.25%.

Levi & Korsinsky is investigating on behalf of Gentex shareholders to evaluate whether potential securities law claims exist. Shareholders who suffered losses may be able to seek recovery whether they still hold GNTX or have already sold. A review of your losses costs nothing and carries no obligation.

Gentex shareholders with losses can have their GNTX losses evaluated today  or call Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP  | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the GNTX Investigation
Q: Who is conducting the GNTX investigation?  A: Levi & Korsinsky, LLP is investigating potential securities law claims on behalf of investors who purchased GNTX securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Who is eligible to participate in the GNTX investigation?  A: Investors who purchased GNTX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do GNTX investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my GNTX shares -- can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought GNTX and sold at a loss may still participate in the investigation.

Q: What if my GNTX losses are small -- is it still worth contacting a lawyer?  A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

Western Union (WU - Free Report) closed the most recent trading day at $6.34, moving -1.4% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.

The money transfer company's stock has climbed by 6.63% in the past month, exceeding the Business Services sector's gain of 3.51% and the S&P 500's loss of 1.21%.

Investors will be eagerly watching for the performance of Western Union in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 4, 2026. It is anticipated that the company will report an EPS of $0.35, marking a 25.53% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.02 billion, indicating a 0.83% decline compared to the corresponding quarter of the prior year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.28 per share and a revenue of $4.08 billion, representing changes of -26.86% and +0.63%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Western Union. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.87% lower. Right now, Western Union possesses a Zacks Rank of #3 (Hold).

In terms of valuation, Western Union is presently being traded at a Forward P/E ratio of 5.03. This represents a discount compared to its industry average Forward P/E of 15.13.

The Financial Transaction Services industry is part of the Business Services sector. Currently, this industry holds a Zacks Industry Rank of 104, positioning it in the top 43% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Main Street Capital (MAIN - Free Report) ended the recent trading session at $53.51, demonstrating a -1.09% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.

Coming into today, shares of the investment firm had lost 1.21% in the past month. In that same time, the Finance sector lost 0.78%, while the S&P 500 lost 1.21%.

The upcoming earnings release of Main Street Capital will be of great interest to investors. The company's earnings report is expected on November 5, 2026. The company is forecasted to report an EPS of $1, showcasing a 3.09% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $144.47 million, up 3.32% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.05 per share and a revenue of $581.54 million, indicating changes of -3.8% and +2.67%, respectively, from the former year.

Investors should also note any recent changes to analyst estimates for Main Street Capital. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.53% fall in the Zacks Consensus EPS estimate. Main Street Capital currently has a Zacks Rank of #3 (Hold).

With respect to valuation, Main Street Capital is currently being traded at a Forward P/E ratio of 13.36. This signifies a premium in comparison to the average Forward P/E of 7.28 for its industry.

The Financial - SBIC & Commercial Industry industry is part of the Finance sector. Currently, this industry holds a Zacks Industry Rank of 76, positioning it in the top 31% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

On October 23, 2026, Dana Inc DAN shares fell 5.0%, bringing the current price to $26.83. Over the past year, shares have fluctuated between a 52-week high of $39.56 and a low of $18.96, resulting in a year-to-date gain of 14.2% and a one-year increase of 37.3%.

GF Value™ verdict: Current price of $26.83 vs GF Value of $16.66, indicating the stock is 61.0% overvalued.GF Score™: 67/100, suggesting the stock is above average in terms of overall quality.Most notable signal: Insiders sold $0.3 million worth of shares over the past 12 months, with no buying activity.Is DAN Overvalued or Undervalued?The current market price of Dana Inc DAN at $26.83 is significantly higher than the GF Value™ estimate of $16.66, which suggests that the stock is overvalued by approximately 61.0%. The GF Value™ is GuruFocus' proprietary intrinsic-value estimate based on historical trading multiples, past business growth, and future performance estimates. Given that Dana Inc is currently unprofitable and cash-flow-negative, relying on earnings-based valuations such as P/E may not provide an accurate picture of the company's true value. Instead, a Price-to-Sales (P/S) analysis is more appropriate in this context.

The GF Valuation label indicates that Dana Inc is significantly overvalued. Investors should be cautious, as the gap between the current price and the estimated fair value represents a considerable margin of safety for potential downturns. This scenario poses risks for current and prospective shareholders, as the stock may face downward pressure if market sentiment shifts or if the company fails to improve its financial performance.

How Does DAN's Valuation Compare to Its History?MetricCurrentHistoricalP/E (5-Year Median)43.4x43.4xForward P/E6.9xN/AWhen examining Dana Inc's valuation metrics, the current P/E ratio of 43.4x aligns with its 5-year median. However, the forward P/E of 6.9x indicates a stark difference, suggesting a potential shift in market expectations. This analysis supports the GF Value™ verdict that the stock is overvalued, as a high P/E ratio typically signifies lofty expectations for future growth, which may not be justified given the company's current cash flow challenges.

What Does DAN's GF Score™ Tell Us?The GF Score™ measures a company's overall quality based on factors such as financial strength, profitability, growth, valuation, and momentum. Dana Inc has a GF Score™ of 67/100, indicating that it is above average compared to its peers. However, the score highlights both strengths and weaknesses across various sub-ranks.

MetricRatingGF Score™67/100Financial Strength5/10Profitability5/10Growth7/10Valuation1/10Momentum10/10The strongest area for Dana Inc lies in its growth rank, which stands at 7/10, indicating potential for future expansion. Conversely, the valuation rank of 1/10 signals significant concerns regarding current pricing relative to intrinsic value. Moreover, the financial strength and profitability ranks of 5/10 suggest that while the company has some stability, it is not performing exceptionally well on these fronts.

What Are Gurus and Insiders Doing with DAN?Currently, six gurus hold positions in Dana Inc, with four increasing their stakes and two reducing their holdings in recent quarters. This activity indicates a mixed sentiment among professional investors regarding the stock's future prospects. While some gurus are optimistic and adding to their positions, others are trimming their exposure, which could suggest caution.

On the insider front, the trend appears bearish, as insiders sold $0.3 million worth of shares over the past 12 months without any buying activity. Such selling can often be viewed as a lack of confidence in the company's future performance, which may concern potential investors.

What This Means for InvestorsConsidering the significant overvaluation indicated by the GF Value™ estimate and the company's unprofitable status, Dana Inc DAN appears to be overvalued at its current price of $26.83. The lack of insider buying further exacerbates the risks associated with the stock. Potential investors should exercise caution and consider these factors before making any investment decisions.

For a deeper dive into Dana Inc's performance metrics and valuation, visit the Dana Inc DAN stock page for more insights.

Frequently Asked QuestionsWhat is DAN's GF Score™?

Dana Inc has a GF Score™ of 67/100, indicating that it is above average when compared to its peers in terms of overall quality.

Is DAN overvalued or undervalued?

According to the GF Value™ estimate, Dana Inc is overvalued, with a current share price of $26.83 significantly exceeding the fair value of $16.66.

What is DAN's P/E ratio?

The trailing P/E ratio for Dana Inc stands at 43.4x, which aligns with its 5-year median, highlighting potential concerns regarding its current valuation level.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

On October 23, 2026, Five9 Inc FIVN shares rose 7.2% to a current price of $37.61, moving within a 52-week range of $13.29 to $40.00. This spike in share price comes amidst a year-to-date increase of 87.6% and a one-year rise of 63.4% despite a slight decline of 0.2% over the last month.

GF Value™ verdict: The current price is $37.61, which is 16.1% above the GF Value™ estimate of $32.39, indicating that FIVN is overvalued.GF Score™ of 79/100, suggesting that the stock is above average in terms of quality and growth potential.Insider activity shows that insiders sold $7.0M worth of shares over the past 12 months without any buying, which may signal caution.Is FIVN Overvalued or Undervalued?The current trading price of Five9 Inc at $37.61 is 16.1% higher than its GF Value™ estimate of $32.39. This indicates that the stock is considered overvalued based on GuruFocus's intrinsic value analysis, which takes into account historical trading multiples, past growth, and future performance potential. With the GF Valuation label marking it as modestly overvalued, this suggests a need for caution for prospective investors, as the margin of safety is limited in this scenario.

Being overvalued poses risks for current and potential investors, particularly if the market corrects or if the company's performance does not meet growth expectations. As a result, while there may be opportunities in the long term, the current valuation may not provide an attractive entry point for new investments.

How Does FIVN's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)54.9x47.8xForward P/E9.8xN/AThe current P/E ratio of 54.9x is significantly above its 5-year median P/E of 47.8x, reflecting a 15% premium to its historical average. Additionally, the forward P/E of 9.8x indicates expectations for lower earnings growth in the near term. This P/E analysis corroborates the GF Value™ verdict, supporting the conclusion that the stock is currently overvalued relative to its historical trading multiples.

What Does FIVN's GF Score™ Tell Us?The GF Score™ is a comprehensive measure that evaluates a stock's quality based on several criteria, including financial strength, profitability, growth, valuation, and momentum. With a GF Score™ of 79/100, Five9 Inc demonstrates above-average potential; however, it also reveals some weaknesses in specific areas.

MetricRatingGF Score™79Financial Strength6/10Profitability4/10Growth9/10Valuation6/10Momentum6/10Five9's strongest ranking is in growth, where it scores 9/10, indicating robust growth potential. However, its profitability rank of 4/10 is a concern, suggesting that while growth prospects are strong, the company's ability to convert that growth into profits is weaker. Overall, the scores imply that while Five9 has a promising growth trajectory, there are challenges regarding its profitability and financial strength that investors should consider.

What Are Gurus and Insiders Doing with FIVN?Currently, six gurus hold shares of Five9 Inc, with three adding to their positions and two trimming their stakes in recent quarters. This mixed signal from guru ownership indicates a divided sentiment among institutional investors, which is noteworthy as it reflects various opinions regarding the stock's future potential.

In contrast, insider activity has not been favorable, with insiders selling $7.0M worth of shares over the past year without any buying activity. This trend might suggest a lack of confidence from those closest to the company regarding its current valuation or future performance, adding a layer of caution for potential investors.

What This Means for InvestorsBased on the analysis of the GF Value™, Five9 Inc is currently overvalued at $37.61, with a GF Value™ estimate of $32.39 reflecting a 16.1% premium. This valuation, coupled with the mixed signals from guru holdings and concerning insider sales, suggests that prospective investors should approach with caution. For more detailed insights on FIVN's performance and metrics, you can visit the Five9 Inc FIVN stock page.

Frequently Asked QuestionsWhat is FIVN's GF Score™?

FIVN has a GF Score™ of 79/100, indicating that it is above average in terms of quality and growth potential.

Is FIVN overvalued or undervalued?

FIVN is currently overvalued as its market price of $37.61 exceeds the GF Value™ estimate of $32.39 by 16.1%.

What is FIVN's P/E ratio?

FIVN's current P/E ratio is 54.9x, which is above its 5-year median P/E of 47.8x, indicating it is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"), of the important December 7, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ensign securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Axcelis Technologies (ACLS - Free Report) closed the most recent trading day at $106.58, moving +1.76% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.52%. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.

Prior to today's trading, shares of the semiconductor services company had lost 9.82% lagged the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.

Market participants will be closely following the financial results of Axcelis Technologies in its upcoming release. The company plans to announce its earnings on November 5, 2026. The company is predicted to post an EPS of $1.11, indicating a 8.26% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $230.05 million, indicating a 7.7% upward movement from the same quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $4.12 per share and revenue of $883.6 million, which would represent changes of -15.57% and +5.31%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Axcelis Technologies. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Axcelis Technologies presently features a Zacks Rank of #3 (Hold).

From a valuation perspective, Axcelis Technologies is currently exchanging hands at a Forward P/E ratio of 25.42. This expresses no noticeable deviation compared to the average Forward P/E of 25.42 of its industry.

Meanwhile, ACLS's PEG ratio is currently 2.63. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Electronics - Manufacturing Machinery industry stood at 1.53 at the close of the market yesterday.

The Electronics - Manufacturing Machinery industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 175, this industry ranks in the bottom 29% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow ACLS in the coming trading sessions, be sure to utilize Zacks.com.

GARDEN GROVE, Calif.--(BUSINESS WIRE)--US Metro Bancorp (OTCQX: USMT): US Metro Bancorp (“Bancorp”) is a bank holding company, with a single subsidiary, US Metro Bank (“Bank”). On a consolidated basis, Bancorp earned $3.1 million in the third quarter of 2026, compared to $3.5 million in the second quarter of 2026. For the nine months ending September 30, 2026, the consolidated Bancorp earned $9.9 million compared to $8.0 million for the nine months ending September 30, 2025. On a year-to-date b.

Are you looking for explosive growth or steady dividends? Investors choosing between Celsius (CELH +0.39%) and Colgate-Palmolive (CL -3.44%) must weigh the revenue potential of the beverage market against the stability of household essential products.

Celsius focuses on the fast-growing functional energy drink market, while Colgate-Palmolive dominates global oral and personal care. These companies represent two very different approaches to consumer goods, offering a choice between a disruptive challenger and a reliable industry titan.

The case for CelsiusCelsius focuses on the beverage category, marketing functional energy drinks to health-conscious consumers. It relies heavily on a distribution partnership with Pepsi, which provides access to vast retail networks and massive scale. Customer concentration like this adds a layer of risk to the business, as sales to this partner accounted for nearly 43.2% of total net revenue as of December 31, 2025. The company also utilizes various independent distributors and e-commerce platforms like Amazon (AMZN -0.95%) and Shopify (SHOP -0.08%) to reach its digital audience.

In its latest annual report, filed for FY 2025, revenue reached nearly $2.5 billion, representing a significant 85.5% increase compared to the previous year. While the top line grew rapidly, the company reported net income of approximately $108 million. This marked a decrease from previous years, reflecting the costs associated with its aggressive expansion and the complex integration of acquired brands like Alani Nu and Rockstar Energy.

Celsius has total cash of $631.2 million and total debt of $674.8 million, and its operating cash flow over the 12-month trailing period is $508.6 million.

CELH Celsius Holdings$28.47+$0.11 (+0.39%)

NASDAQ · As of 4:00 PM ET 10/23/26

The case for Colgate-PalmoliveColgate-Palmolive is a global consumer products leader specializing in oral care, personal care, home care, and pet nutrition. It maintains a recurring revenue model driven by regular product replenishment. A significant customer relationship with Walmart (WMT -1.02%) accounted for approximately 11% of its total net sales in 2025, and customer concentration like this adds a layer of risk to the business.

According to its latest annual report for FY 2025, revenue reached close to $20.4 billion, which was a modest increase over the prior year. The company generated net income of approximately $2.1 billion during this period. These figures highlight the steady, though slower, growth typical of a large consumer staples company.

Colgate has total cash of $1.4 billion and total debt of $7.8 billion, and its total debt-to-equity ratio over the 12-month trailing period is $4.4 billion.

$94.04-$3.35 (-3.44%)

NYSE · As of 4:00 PM ET 10/23/26

Risk profile comparisonCelsius faces significant risks from its heavy dependency on Pepsi for distribution and commercial strategy. Any termination of these agreements or a significant disagreement would have a material adverse effect on operations, especially given Pepsi's ownership stake and Board representation. The company is also currently facing multiple securities class action lawsuits and intense competition from larger rivals such as Red Bull and Monster Beverage (MNST -2.35%).

Colgate-Palmolive is exposed to macroeconomic and geopolitical instability due to its vast global operations and complex supply chain. Inflationary pressures and currency fluctuations can drive up costs for raw materials, logistics, and labor across different regions. Furthermore, the company faces vigorous competition from both multinational brands and private-label products, requiring constant adaptation to shifts in the digital retail landscape.

Valuation comparisonCelsius appears more attractively valued than Colgate-Palmolive when looking at traditional metrics, but that doesn't tell the full story.

MetricCelsiusColgate-PalmoliveForward P/E16.8x20.9xP/S ratio2.4x3.2xWhich stock would I buy?These two companies offer an interesting dynamic by comparing a growth stock against a more mature company that's a Dividend King, having boosted its dividend payout for 50 or more consecutive years. Colgate has increased its dividend payout for 63 consecutive years. While each company has different dynamics, I would rather invest in Colgate over Celsius due to its more defensive nature and consistent dividend payouts. In a time where people are trying to stretch each dollar as far as possible, they may cut back on energy drinks, but they won't cut back on the household essentials Colgate-Palmolive offers.

While Celsius has shown explosive stock price growth, shareholders have also seen significant stock price declines, and the Celsius stock price is down nearly 54% over the last 12 months. In comparison, Colgate shares are up nearly 22%, easily outperforming not only Celsius but also the S&P 500's 14.3% return. Between the two, especially amid so much market uncertainty, I would rather own the steady performer that pays consistent dividends.

Energy Transfer LP (ET - Free Report) closed the most recent trading day at $20.45, moving +2.05% from the previous trading session. This change outpaced the S&P 500's 0.52% loss on the day. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.

Heading into today, shares of the energy-related services provider had lost 1.43% over the past month, lagging the Oils-Energy sector's gain of 5.63% and the S&P 500's loss of 1.21%.

Market participants will be closely following the financial results of Energy Transfer LP in its upcoming release. The company plans to announce its earnings on November 3, 2026. On that day, Energy Transfer LP is projected to report earnings of $0.41 per share, which would represent year-over-year growth of 46.43%. Meanwhile, our latest consensus estimate is calling for revenue of $35.6 billion, up 78.41% from the prior-year quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.73 per share and a revenue of $122.42 billion, signifying shifts of +42.98% and +43.13%, respectively, from the last year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Energy Transfer LP. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.12% higher within the past month. Energy Transfer LP is currently a Zacks Rank #3 (Hold).

Valuation is also important, so investors should note that Energy Transfer LP has a Forward P/E ratio of 11.57 right now. This represents a discount compared to its industry average Forward P/E of 14.7.

Meanwhile, ET's PEG ratio is currently 0.7. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Oil and Gas - Production Pipeline - MLB stocks are, on average, holding a PEG ratio of 1.59 based on yesterday's closing prices.

The Oil and Gas - Production Pipeline - MLB industry is part of the Oils-Energy sector. Currently, this industry holds a Zacks Industry Rank of 27, positioning it in the top 11% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

In the latest close session, Freshpet (FRPT - Free Report) was down 4.3% at $64.12. The stock's change was less than the S&P 500's daily loss of 0.52%. At the same time, the Dow lost 1.24%, and the tech-heavy Nasdaq lost 0.21%.

The seller of refrigerated fresh pet food's stock has climbed by 14.9% in the past month, exceeding the Consumer Staples sector's gain of 6.6% and the S&P 500's loss of 1.21%.

The investment community will be paying close attention to the earnings performance of Freshpet in its upcoming release. The company is slated to reveal its earnings on November 4, 2026. The company is forecasted to report an EPS of $0.35, showcasing a 23.91% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $309.77 million, indicating a 7.24% increase compared to the same quarter of the previous year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.25 per share and revenue of $1.22 billion, indicating changes of -52.65% and +10.92%, respectively, compared to the previous year.

Investors should also take note of any recent adjustments to analyst estimates for Freshpet. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.58% decrease. Freshpet is holding a Zacks Rank of #3 (Hold) right now.

Investors should also note Freshpet's current valuation metrics, including its Forward P/E ratio of 53.81. This signifies a premium in comparison to the average Forward P/E of 15.26 for its industry.

The Food - Miscellaneous industry is part of the Consumer Staples sector. This industry currently has a Zacks Industry Rank of 202, which puts it in the bottom 18% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow FRPT in the coming trading sessions, be sure to utilize Zacks.com.